Although not a personalized therapy, the remarkable achievements of the FDA approved VEGF inhibitor ranibizumab in achieving disease control in neovascular AMD represents a triumph of molecular medicine, developed from a better understanding of the pathophysiology of AMD. The gene discussed is VEGFA; the disease is age-related macular degeneration.